Seroquel on Glucose Metabolism
Phase 4
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT00214578
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 572
Inclusion Criteria
- In- or outpatients with schizophrenia, 18-65 years old, requiring a change in treatment due to insufficient efficacy or tolerability and giving signed informed consent.
Exclusion Criteria
- Known diabetes mellitus, high HbA1c, fasting plasma glucose and/or high 2h glucose-OGTT.
- Previous use of atypicals (3 months) or other medications that might influence glucose metabolism
- Contraindications or non-responsiveness for any of the treatments or other safety issues
- Expected non-compliance to treatment and/or study procedures
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To analyze the safety/tolerability profile of quetiapine on glucose metabolism in schizophrenic patients
- Secondary Outcome Measures
Name Time Method Glucose metabolism, blood lipid levels and weight
Trial Locations
- Locations (1)
Research Site
🇬🇧Birmingham, United Kingdom